Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1331

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1331
---
 preclinical studies and clinical trials;

    ●
    the
    scope, prioritization and number of our clinical trials and other research and development programs;

    ●
    the
    amount of revenues we receive under future licensing, collaboration, development and commercialization arrangements with respect
    to our product candidates; 

    ●
    the
    impact of any pandemic, epidemic or other future health crisis on our business and operations;

     ●
    the
    costs of the development and expansion of our operational infrastructure; 

    ●
    the
    costs, timing and outcome of regulatory review of our product candidates;

    ●
    the
    ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
    our potential future licensing agreements; 

    ●
    the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; 

    ●
    the
    costs and timing of securing manufacturing arrangements for clinical or commercial production;

    ●
    the
    costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves;

    ●
    the
    costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology;

     ●
    the
    costs associated with being a public company; and

     ●
    any
    cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.

27

Even
if we believe we have sufficient funds for our current or future operating plans, we may continue to seek additional capital if market
conditions are favorable or in light of specific strategic considerations. Adequate additional financing may not be available to us on
acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis, in required amounts or on favorable terms,
we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization
efforts. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events
could materially adversely affect our financial condition and business prospects.

Raising
additional capital would cause dilution to our shareholders and may restrict our operations or require us to relinquish rights to our
technologies or product candidates.

Until
such